Studies have reported that Ki-67 expression rates and HER2 and other biological markers are prognostically significant markers in DCIS patients (Roka et al. 2004; Ringberg et al. 2001; Provenzano et al. 2003; de Roos et al. 2007; Menter et al. 2001; Barnes et al. 2005). This evidence concerns the gene MKI67 and ductal breast carcinoma in situ.